Zobrazeno 1 - 10
of 613
pro vyhledávání: '"Ascher-Svanum H"'
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1287-1296 (2014)
William Montgomery,1 Tamas Treuer,2 Wenyu Ye,3 Hai Bo Xue,4 Sheng Hu Wu,4 Li Liu,4 Zbigniew Kadziola,5 Michael D Stensland,6 Haya Ascher-Svanum7 1Global Health Outcomes Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 2Neuroscience Research, E
Externí odkaz:
https://doaj.org/article/5605d906b7e540bd83b90fbc0a58c7ff
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1125-1131 (2014)
Haya Ascher-Svanum,1 Diego Novick,2,3 Josep Maria Haro,4 Jordan Bertsch,4 David McDonnell,1 Holland Detke11Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly and Company, Windlesham, Surrey, UK; 3Departament de Psiquiatria, Universitat Autonoma
Externí odkaz:
https://doaj.org/article/12667f4e45cf4e3fa8a25fb83321066f
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol 2013, Iss default, Pp 407-418 (2013)
William Montgomery,1 Li Liu,2 Michael D Stensland,5 Hai Bo Xue,2 Tamas Treuer,4 Haya Ascher-Svanum31Eli Lilly and Company, Sydney, NSW, Australia; 2Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People's Republic of China; 3Eli Lilly and Company
Externí odkaz:
https://doaj.org/article/4cff3c471c504abbb336ee608f5b73c3
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 815-822 (2013)
Lei Chen, Haya Ascher-Svanum, Anthony Lawson, Virginia L Stauffer, Allen Nyhuis, Virginia Haynes, Kory Schuh, Bruce J KinonEli Lilly and Company, Indianapolis, IN, USABackground: This study identified subgroups of patients with schizophrenia who diff
Externí odkaz:
https://doaj.org/article/af6c890d7ccc431bb472958c0c9517b2
Autor:
Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D
Publikováno v:
Patient Preference and Adherence, Vol 2012, Iss default, Pp 521-532 (2012)
Louis S Matza,1 Glenn A Phillips,2 Dennis A Revicki,1 Haya Ascher-Svanum,3 Karen G Malley,4 Andrew C Palsgrove,1 Douglas E Faries,3 Virginia Stauffer,3 Bruce J Kinon,3 A George Awad,5 Richard SE Keefe,6 Dieter Naber71Outcomes Research, United BioSour
Externí odkaz:
https://doaj.org/article/2e308b2fb00f4386afb38c6fcf19255b
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 259-266 (2012)
Wenyu Ye,1 Haya Ascher-Svanum,2 Yuka Tanji,3 Jennifer A Flynn,3 Michihiro Takahashi,3,4 Robert R Conley21Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai, People’s Republic of China; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Lilly Research Labor
Externí odkaz:
https://doaj.org/article/bd088a5a901348708a0a804aa632c09a
Publikováno v:
International Journal of General Medicine, Vol 2012, Iss default, Pp 391-398 (2012)
Haya Ascher-Svanum1, William S Montgomery2, David P McDonnell3, Kristina A Coleman4, Peter D Feldman11Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly Australia Pty Ltd, West Ryde, New South Wales, Australia; 3Eli
Externí odkaz:
https://doaj.org/article/e8c247bccf0348229d59911b30ff8a7f
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 113-118 (2012)
Haya Ascher-Svanum, Alan JM Brnabic, Anthony H Lawson, Bruce J Kinon, Virginia L Stauffer, Peter D Feldman, Katarina KelinLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USAAbstract: It is often diff
Externí odkaz:
https://doaj.org/article/1a59ce1d9d3647b4ae4f1f2406b6344b
Publikováno v:
Patient Preference and Adherence, Vol 2012, Iss default, Pp 109-125 (2012)
William Montgomery1, Tamas Treuer2, Jamie Karagianis3, Haya Ascher-Svanum4, Gavan Harrison51Global Health Outcomes, Eli Lilly and Company, Sydney, Australia; 2Emerging Markets Business Unit (Neuroscience), Eli Lilly and Company, Budapest, Hungary; 3E
Externí odkaz:
https://doaj.org/article/35000538854c42c9833f9617a87801b3
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol 2012, Iss default, Pp 13-19 (2012)
Wenyu Ye1, Haya Ascher-Svanum2, Jennifer A Flynn3, Yuka Tanji3, Michihiro Takahashi3,41Lilly Suzhou Pharmaceutical Co, Shanghai, People's Republic of China; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Lilly Research Laboratories Japan, Eli Lilly
Externí odkaz:
https://doaj.org/article/28b7d8f18e4d48b4b6bb11310578e3cc